These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35806868)

  • 1. Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan.
    Morioka I; Kakei Y; Omori T; Nozu K; Fujioka K; Takahashi N; Yoshikawa T; Moriuchi H; Ito Y; Oka A;
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT Compliant).
    Morioka I; Kakei Y; Omori T; Nozu K; Fujioka K; Yoshikawa T; Moriuchi H; Ito Y; Oka A
    Medicine (Baltimore); 2020 Apr; 99(17):e19765. PubMed ID: 32332615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of patients' characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease.
    Kakei Y; Morioka I; Imai T; Itohara K; Yano I; Takahashi N; Yoshikawa T; Moriuchi H; Ito Y; Fujioka K; Oka A;
    J Infect Chemother; 2024 Oct; 30(10):971-977. PubMed ID: 38484931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection.
    Ohyama S; Morioka I; Fukushima S; Yamana K; Nishida K; Iwatani S; Fujioka K; Matsumoto H; Imanishi T; Nakamachi Y; Deguchi M; Tanimura K; Iijima K; Yamada H
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection.
    Suganuma E; Sakata H; Adachi N; Asanuma S; Furuichi M; Uejima Y; Sato S; Abe T; Matsumoto D; Takahashi R; Yamamoto S; Kawano Y; Arai T; Oh-Ishi T
    J Infect Chemother; 2021 Feb; 27(2):185-191. PubMed ID: 32907793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
    Togashi J; Sugawara Y; Hashimoto M; Tamura S; Kaneko J; Aoki T; Hasegawa K; Kokudo N
    Biosci Trends; 2011; 5(5):217-22. PubMed ID: 22101378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland.
    Jedlińska-Pijanowska D; Czech-Kowalska J; Kłodzińska M; Pietrzyk A; Michalska E; Gradowska K; Dobrzańska A; Kasztelewicz B; Gruszfeld D
    Adv Clin Exp Med; 2020 Oct; 29(10):1161-1167. PubMed ID: 33053275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Valganciclovir in Congenital Cytomegalovirus Infection with Isolated Intrahepatic Cholestasis: A Randomized Controlled Trial.
    Mahmud S; Farhana T; Anik AM; Ahmed F; Parvez M; Baidya M; Rashid R; Tasneem F; Hasan AR; Alam MJ; Muaz SA
    Pediatr Gastroenterol Hepatol Nutr; 2024 Sep; 27(5):298-312. PubMed ID: 39319277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening.
    Kawada J; Torii Y; Kawano Y; Suzuki M; Kamiya Y; Kotani T; Kikkawa F; Kimura H; Ito Y
    J Clin Virol; 2015 Apr; 65():41-5. PubMed ID: 25766986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.
    Meine Jansen CF; Toet MC; Rademaker CM; Ververs TF; Gerards LJ; van Loon AM
    J Perinat Med; 2005; 33(4):364-6. PubMed ID: 16211780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment.
    Torii Y; Morioka I; Kakei Y; Fujioka K; Kakimoto Y; Takahashi N; Yoshikawa T; Moriuchi H; Oka A; Ito Y
    BMC Infect Dis; 2023 Jan; 23(1):31. PubMed ID: 36658533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S
    Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period.
    del Rosal T; Baquero-Artigao F; Blázquez D; Noguera-Julian A; Moreno-Pérez D; Reyes A; Vilas J
    J Clin Virol; 2012 Sep; 55(1):72-4. PubMed ID: 22750017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cohort study of the universal neonatal urine screening for congenital cytomegalovirus infection.
    Yamada H; Tanimura K; Fukushima S; Fujioka K; Deguchi M; Sasagawa Y; Tairaku S; Funakoshi T; Morioka I
    J Infect Chemother; 2020 Aug; 26(8):790-794. PubMed ID: 32273174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant recipients: a single-center experience.
    Iida T; Miura K; Ban H; Ando T; Shirai Y; Ishiwa S; Shiratori A; Kaneko N; Yabuuchi T; Ishizuka K; Takaiwa M; Suyama K; Hisano M; Hattori M
    Clin Exp Nephrol; 2021 May; 25(5):531-536. PubMed ID: 33506359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.